Document:

Exhibit 10.2

 

CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS ARE MARKED WITH [*****] AND HAVE BEEN FILED SEPARATELY WITH THE SEC.

 

CROSS-LICENSE AGREEMENT

 

This Cross-License Agreement is made by and between OncoSec Medical Incorporated (“ONCSD”), a Nevada corporation, with its principal place of business at 8th Floor - 200 Virginia Street, Reno NV 89501, and Inovio Pharmaceuticals, Inc. (“INO”), a Delaware corporation, with its principal place of business at 1787 Sentry Parkway West, Building 18, Suite 400, Blue Bell, PA 19422.

 

WHEREAS, ONCSD owns or controls certain intellectual property related to electroporation facilitated delivery of chemotherapeutic agents, or nucleic acids encoding cytokines for use as active agent only, into tumors and/or surrounding tissue (or tumor margin tissue) in humans for the treatment and diagnosis of benign and malignant tumors, and wishes to provide a license thereunder to INO;

 

WHEREAS, INO owns or controls certain intellectual property related to various electroporation devices and their use, and wishes to provide a license thereunder to ONCSD; and

 

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereby agree as follows:

 

1.       DEFINITIONS

 

1.1           AFFILIATE means any corporation, firm, limited liability company, partnership, or other entity that directly or indirectly controls, or is controlled by, or is under common control with a Party to this AGREEMENT. For the purpose of this definition, “control” means ownership, directly or through one or more AFFILIATES, of fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign entity in a particular jurisdiction) or more of the shares of stock entitled to vote for the election of directors in the case of a corporation, or fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign entity in a particular jurisdiction) or more of the equity interests in the case of any other type of legal entity, or status as a general partner in any partnership, or any other arrangement whereby a Party controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity.

 

1.2           AGREEMENT means this Cross-License Agreement made by and between OncoSec Medical Incorporated (“ONCSD”) and Inovio Pharmaceuticals, Inc. (INO), including any recitals and Schedules to this agreement, as amended, supplemented or restated from time to time.

 

1.3           EFFECTIVE DATE means the date on which ONCSD and INO have both fully executed this AGREEMENT.

 

1.4           EXCLUDED PROCEEDS means all proceeds reasonably and fairly attributable to bona fide [*****]

 

 

CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS ARE MARKED WITH [*****] AND HAVE BEEN FILED SEPARATELY WITH THE SEC.

 

[*****]

 

1.5           FAIR MARKET VALUE means the cash consideration which ONCSD or a sublicensee thereof would realize from an unaffiliated, unrelated buyer in an arm’s length sale of an identical item sold in the same quantity and at the same time and place of the transaction.

 

1.6           INO FIELD means the use of electroporation to deliver genes and/or nucleic acids, outside of those encoding cytokines as active agent only.

 

1.7           INO PATENT RIGHTS means the rights conferred by the patents listed in Appendix B, including rights to any continuation, continuation-in-part, divisional, renewal, reissue, reexamination, derivative, and foreign counterpart patents thereof.

 

1.8           NET SALES means the gross amount invoiced for SALES, less qualifying costs directly attributable to such SALES and actually identified on the invoice and borne by ONCSD or its sublicensee(s).  Such qualifying costs shall be limited to the following:

 

1.8.1        [*****]

 

1.8.2        [*****]

 

1.8.3        [*****]

 

1.8.4        [*****]

 

1.8.5        [*****]

 

For clarity, NET SALES shall specifically exclude all EXCLUDED PROCEEDS.

 

1.9           ONCSD FIELD means the use of electroporation to facilitate delivery of chemotherapeutic agents, or nucleic acids encoding cytokines for use as active agent only, into tumors and/or surrounding tissue (or tumor margin tissue) in humans for the treatment and diagnosis of benign and malignant tumors.

 

1.10         ONCSD PATENT RIGHTS means the rights conferred by the patents listed in Appendix A, including rights to any continuation, continuation-in-part, divisional, renewal, reissue, reexamination, derivative, and foreign counterpart patents thereof.

 

 

CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS ARE MARKED WITH [*****] AND HAVE BEEN FILED SEPARATELY WITH THE SEC.

 

1.11         PATENTS mean any U.S. and foreign patents, patent applications, and provisional patent applications; U.S. and foreign patents issued from such applications and from any divisional, continuations, or continuations-in-part; reexamination, derivative, and any renewals or reissues thereof.

 

1.12         SALE means any bona fide transaction for which consideration is received or promised for the sale, use, lease, transfer or other disposition of SECTA TECHNOLOGY to an unrelated third party. A SALE of SECTA TECHNOLOGY shall be deemed completed at the time ONCSD or its sublicensee receives payment for such SECTA TECHNOLOGY.

 

1.13         SECTA shall mean electroporation facilitated delivery of chemotherapeutic agents, or nucleic acids encoding cytokines for use as active agent only, into tumors and/or surrounding tissue (or tumor margin tissue) in humans for the treatment and diagnosis of benign and malignant tumors.

 

1.14         SECTA BUSINESS shall mean:

 

1.14.1      any products or services that are made or designed from or with the aid of the SECTA Technology; or

 

uses of  the SECTA Technology.

 

1.15         SECTA TECHNOLOGY means all SECTA related technologies, inventions, arts, processes, business methods, developments, patent rights, know-how, registrations, applications for registration, data, information (financial or otherwise), products, devices, documentation, engineering and quality documentation, moulds, machinery, diagrams, and inventory and other intellectual, industrial, tangible or intangible property relating primarily to the Field of Use, whether or not patented or the subject of a patent application, including all trademarks, brands and know-how.

 

2.             LICENSE GRANT

 

2.1           ONCSD hereby grants to INO a fully paid up, exclusive, worldwide license in the INO FIELD under the ONCSD PATENT RIGHTS (the “ONCSD LICENSE”).

 

2.2           INO hereby grants to ONCSD a non-exclusive, worldwide license in the ONCSD FIELD under the INO PATENT RIGHTS (the “INO LICENSE”).

 

3.             FEES AND ROYALTIES

 

3.1           Fees

 

3.1.1        INO Fees

 

3.1.1.1       For avoidance of doubt, INO does not owe ONCSD any upfront fees [*****] in exchange for the ONCSD LICENSE.

 

 

CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS ARE MARKED WITH [*****] AND HAVE BEEN FILED SEPARATELY WITH THE SEC.

 

3.1.1.2       ONCSD Fees

 

3.1.1.3       For avoidance of doubt, ONCSD does not owe any upfront fees [*****] in exchange for the INO LICENSE.

 

3.1.1.4       ONSC shall pay to INO [*****] of any fee or payment in cash or equity that ONSC receives in return for a sublicense to a third party of the INO PATENT RIGHTS, but excludes any amounts received by ONSC as a form of investment or financing.

 

3.1.1.5       ONCSD shall pay and/or reimburse INO for any amounts [*****] that is a direct result of this non-exclusive license to ONCSD.

 

3.2           Royalties

 

3.2.1        INO Royalties

 

3.2.1.1       For avoidance of doubt, INO does not owe ONCSD any royalty fees in exchange for the ONCSD LICENSE.

 

3.2.2        ONCSD Royalties

 

3.2.2.1       In exchange for the INO LICENSE, ONCSD shall pay to INO a royalty of [*****] on NET SALES of SECTA BUSINESS.

 

3.3           Currency, Payment Method.

 

3.3.1        All dollar amounts referred to in this AGREEMENT are United States dollars.  All payments to INO under this AGREEMENT shall be made in United States dollars by check payable to “Inovio Pharmaceuticals.”

 

3.3.2        Amounts that are not paid when due shall accrue interest from the due date until paid, at a rate equal to [*****] per month (or maximum allowed by law, if less).

 

4.             CONFIDENTIALITY

 

4.1           CONFIDENTIAL INFORMATION means and includes all technical and business information, plans, inventions, developments, discoveries, improvements, software, know-how, procedures, methods, techniques, formulae, data, processes, studies, and other proprietary ideas, whether or not patentable or copyrightable, that a party hereto identifies as confidential or proprietary at the time it is delivered or communicated to the other party hereto, or any other information that should reasonably be recognizable by its nature to be confidential or trade secret information of a party (including, without limitation, information respecting such party’s business plans, sales and sales methods, customers and prospective customers). CONFIDENTIAL INFORMATION should be in writing and marked confidential or, if oral, should be reduced to writing within two weeks of disclosure and marked confidential.

 

 

4.2           Each party shall maintain in confidence and not disclose to any third party any CONFIDENTIAL INFORMATION of the other party for the term of this AGREEMENT and for five (5) years thereafter.  Each party shall ensure that its employees have access to CONFIDENTIAL INFORMATION of the other party only on a need-to-know basis, and are obligated to abide by such party’s obligations under this AGREEMENT.  The foregoing obligation shall not apply to the below exceptions:

 

4.2.1        information that is known to the receiving party prior to the time of disclosure, and was not received directly or indirectly from the disclosing party hereunder in violation of a confidentiality obligation, unless received subject to non-disclosure and non-use obligations, or independently developed by or for the receiving party, without exposure to or benefit of the disclosing party’s CONFIDENTIAL INFORMATION, in each case, to the extent evidenced by written records;

 

4.2.2        information disclosed to the receiving party, without restriction, by a third party that has a right to make such disclosure;

 

4.2.3        information that was or becomes patented, published or otherwise part of the public domain as a result of acts by the disclosing party or a third person developing or obtaining such information as a matter of right; and

 

4.2.4        information which the disclosing party permits, in writing, the receiving party to publicly disclose.

 

4.3           If a receiving party is required to disclose any of the disclosing party’s CONFIDENTIAL INFORMATION by order of a governmental authority or a court of competent jurisdiction; the receiving party shall timely inform its disclosing party, reasonably cooperate at the disclosing parties expense with any reasonable action the disclosing party takes to attempt to obtain confidential treatment of such information by the authority or court, and limit its disclosure of such information to the extent practical.

 

5.             TERM AND TERMINATION

 

5.1           This AGREEMENT, unless sooner terminated as provided in this AGREEMENT, shall terminate upon the earlier of: (a) the expiration or abandonment of the last patent that is either a patent of INO PATENT RIGHTS or ONCSD PATENT RIGHTS; or (b) twenty (20) years after the EFFECTIVE DATE.

 

5.2           ONCSD may terminate this AGREEMENT upon thirty (30)-days written notice to INO; and by completing all the following:

 

 

CONFIDENTIAL TREATMENT REQUESTED.  OMITTED PORTIONS ARE MARKED WITH [*****] AND HAVE BEEN FILED SEPARATELY WITH THE SEC.

 

5.2.1        ceasing to make, have made, use, import, sell and offer for sale all products or services covered by the INO PATENT RIGHTS;

 

5.2.2        terminating all sublicenses relating to the INO PATENT RIGHTS, and causing all sublicensees to cease making, having made, using, importing, selling and offering for sale all products and services covered by the INO PATENT RIGHTS; and

 

5.2.3        paying all monies owed to INO under this AGREEMENT.

 

5.3           INO may terminate this AGREEMENT upon thirty (30)-days written notice to ONCSD; and by completing all the following:

 

5.3.1        ceasing to make, have made, use, import, sell and offer for sale all products or services covered by the ONCSD PATENT RIGHTS; and

 

5.3.2        terminating all sublicenses relating to the ONCSD PATENT RIGHTS, and causing all sublicensees to cease making, having made, using, importing, selling and offering for sale all products and services covered by the ONCSD PATENT RIGHTS.

 

5.4           ONCSD may terminate this AGREEMENT, upon ten (10)-days written notice to INO, if any of the following events of default occur:

 

5.4.1        INO experiences a Trigger Event (defined in Section 5.6, below);

 

5.4.2        INO materially breaches this AGREEMENT and does not cure the material breach within thirty (30) days after written notice of such material breach.

 

5.5           INO may terminate this AGREEMENT, upon ten (10)-days written notice to ONCSD, if any of the following events of default occur:

 

5.5.1        ONCSD is more than [*****] late in paying INO any royalties, expenses or any other monies due under this AGREEMENT and ONCSD does not immediately pay INO in full any amounts due upon written demand; or

 

5.5.2        ONCSD experiences a Trigger Event (defined in Section 5.6, below);

 

5.5.3        subject to 5.5.1, ONCSD materially breaches this AGREEMENT and does not cure the material breach within thirty (30) days after written notice of such material breach.

 

5.6           “Trigger Event” means any of the following:

 

5.6.1        If a Party:

 

 

5.6.1.1       becomes insolvent, bankrupt or generally fails to pay its material debts as such debts become due;

 

5.6.1.2       is adjudicated insolvent or bankrupt; admits in writing its inability to pay its debts; or shall suffer a custodian, receiver or trustee for it or substantially all of its property to be appointed and, if appointed without its consent, is not discharged within thirty (30) days of such appointment; or

 

5.6.1.3       makes an assignment for the benefit of creditors; or suffers proceedings under any law related to bankruptcy, insolvency, liquidation or the reorganization, readjustment or the release of debtors to be instituted against it and, if contested by it, not dismissed or stayed within thirty (30) days;

 

5.6.2        If proceedings under any United States law related to bankruptcy, insolvency, liquidation, or the reorganization, readjustment or the release of debtors are instituted or commenced by such Party;

 

5.6.3        If any order for relief is entered relating to any of the proceedings described in Section 5.6;

 

5.6.4        If such Party shall call a meeting of its creditors with a view to arranging a composition or adjustment of its debts; or

 

5.6.5        If such Party shall, by any act or failure to act, indicate its consent to, approval of or acquiescence in any of the proceedings described in Section 5.6.

 

5.7           Upon and after any termination of this AGREEMENT, ONCSD and any sublicensee thereof shall refrain from further manufacture, sale, marketing, importation and/or distribution of any product or service covered by the INO PATENT RIGHTS, and INO and any sublicensee thereof shall refrain from further manufacture, sale, marketing, importation and/or distribution of any product or service covered by the ONCSD PATENT RIGHTS.

 

5.8           Upon termination of this AGREEMENT, each (receiving) party shall, at the other (disclosing) party’s request, return to the other party all CONFIDENTIAL INFORMATION (except for one copy for archival purposes, to the extent required by law) of the other party provided hereunder.

 

5.9           Each party’s obligation to pay all monies owed and accruing as of the date of termination under this AGREEMENT shall survive termination of this AGREEMENT.

 

 

6.             IMPROVEMENTS TO INVENTIONS

 

6.1           When an improvement to the INO PATENT RIGHTS is conceived or reduced to practice by ONCSD and/or its sublicensee(s), ONCSD and/or its sublicense(s) hereby assign their entire right, title and interest in such improvement to INO.  Furthermore, ONCSD and/or sublicense(s) agree to cooperate with INO in obtaining patent protection to such improvement at INO’s cost, including but not limited to the execution of any and all lawful papers in the U.S. and foreign patent offices.  INO hereby grants ONCSD a license in ONCSD FIELD to such improvements and under any resulting patents related to such improvement under similar terms as that provided for INO PATENT RIGHTS under this AGREEMENT.

 

6.2           When an improvement to the ONCSD PATENT RIGHTS is conceived or reduced to practice by INO and/or its sublicensee(s), INO and/or its sublicense(s) hereby assign their entire right, title and interest in such improvement to ONCSD.  Furthermore, INO and/or sublicense(s) agree to cooperate with ONCSD in obtaining patent protection to such improvement at ONCSD’s cost, including but not limited to the execution of any and all lawful papers in the U.S. and foreign patent offices.  ONCSD hereby grants INO a license in INO FIELD to such improvements and under any resulting patents related to such improvement under similar terms as that provided for ONCSD PATENT RIGHTS under this AGREEMENT.

 

7.             INFRINGEMENT AND LITIGATION

 

7.1           INO and ONCSD are responsible for notifying each other promptly of any known or suspected infringement of ONCSD PATENT RIGHTS and INO PATENT RIGHTS, respectively, which may come to their attention after the EFFECTIVE DATE.  INO and ONCSD shall consult one another in a timely manner concerning an appropriate response to the infringement.

 

7.2           ONCSD may prosecute infringement of the INO PATENT RIGHTS at its own expense.  ONCSD shall not settle or compromise any such suit in a manner that imposes any obligations or restrictions on INO or grants any rights to the INO PATENT RIGHTS, without INO’s prior written permission.  Financial recoveries from any such litigation will first be applied to reimburse ONCSD for its litigation expenditures with additional recoveries being paid to ONCSD, subject to lost royalty due INO based on such infringement.

 

7.3           INO may prosecute infringement of the ONCSD PATENT RIGHTS at its own expense.  INO shall not settle or compromise any such suit in a manner that imposes any obligations or restrictions on ONCSD or grants any rights to the ONCSD PATENT RIGHTS, without ONCSD’s prior written permission.  Financial recoveries from any such litigation will first be applied to reimburse INO for its litigation expenditures with additional recoveries being paid to INO, subject to lost royalty due ONCSD based on such infringement.

 

7.4           ONCSD’s rights under Section 7.2 are subject to the continuing right of INO to intervene at INO’s own expense and join ONCSD in any claim or suit for infringement of the INO PATENT RIGHTS.  Any consideration received by INO or ONCSD in settlement of any claim or suit shall be shared between INO and ONCSD in proportion with each party’s share of the litigation expenses reasonably incurred in such infringement action.

 

 

7.5           INO’s rights under Section 7.3 are subject to the continuing right of ONCSD to intervene at ONCSD’s own expense and join INO in any claim or suit for infringement of the ONCSD PATENT RIGHTS.  Any consideration received by INO or ONCSD in settlement of any claim or suit shall be shared between INO and ONCSD in proportion with each party’s share of the litigation expenses reasonably incurred in such infringement action.

 

7.6           If ONCSD fails to prosecute any material infringement of INO PATENT RIGHTS, INO may prosecute such material infringement at its own expense.  In such event, financial recoveries will be entirely retained by INO.

 

7.7           If INO fails to prosecute any material infringement of ONCSD PATENT RIGHTS, ONCSD may prosecute such material infringement at its own expense.  In such event, financial recoveries will be entirely retained by ONCSD.

 

7.8           In any action to enforce any of the INO PATENT RIGHTS, or the ONCSD PATENT RIGHTS, either party, at the request and reasonable expense of the other party, shall cooperate to the fullest extent reasonably possible.  This provision shall not be construed to require either party to undertake any activities, including legal discovery, at the request of any third party, except as may be required by lawful process of a court of competent jurisdiction.

 

7.9           INO agrees and covenants not to sue ONCSD for patent infringement for ONCSD’s practice in the ONCSD FIELD based on patents owned or controlled (having rights to sue) by INO other than the INO PATENT RIGHTS provided ONCSD has not breached any of its obligations under this Agreement. However, in return, ONCSD agrees not to challenge the validity, ownership, inventorship, or other related right associated with a INO owned or licensed patent.

 

7.10         ONCSD agrees and covenants not to sue INO for patent infringement for INO’s practice in the INO FIELD based on patents owned or controlled (having rights to sue) by ONCSD other than the ONCSD PATENT RIGHTS provided INO has not breached any of its obligations under this Agreement. However, in return, INO agrees not to challenge the validity, ownership, inventorship, or other related right associated with a ONCSD owned or licensed patent.

 

8.                                       REPRESENTATIONS AND WARRANTIES; DISCLAIMER OF ADDITIONAL WARRANTIES; INDEMNIFICATION

 

8.1           INO represents and warrants to ONCSD that to its knowledge as of the date hereof:

 

8.1.1        INO has the full authority to execute and deliver this AGREEMENT.

 

 

8.1.2        No material claim by any third party contesting the validity, enforceability, licensability, use or ownership of any of such INO PATENT RIGHTS has been made, is currently outstanding or is threatened against INO.

 

8.1.3        No loss or expiration of any part of the INO PATENT RIGHTS is currently pending.

 

8.2           ONCSD represents and warrants to INO that to its knowledge as of the date hereof:

 

8.2.1        ONCSD has the full authority to execute and deliver this AGREEMENT.

 

8.2.2        No material claim by any third party contesting the validity, enforceability, licensability, use or ownership of any of such ONCSD PATENT RIGHTS has been made, is currently outstanding or is threatened against ONCSD.

 

8.2.3        No loss or expiration of any part of the ONCSD PATENT RIGHTS is currently pending.

 

8.3           EXCEPT AS SET FORTH IN SECTION 8.1, ALL TECHNOLOGY LICENSED UNDER THE INO PATENT RIGHTS IN THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS AND INO MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT THERETO.  BY WAY OF EXAMPLE, BUT NOT OF LIMITATION, INO MAKES NO REPRESENTATIONS OR WARRANTIES (i) OF COMMERCIAL UTILITY; (ii) OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE; OR (iii) THAT THE USE OF THE LICENSED TECHNOLOGY UNDER THIS AGREEMENT WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADE SECRET OR TRADEMARK OR OTHER PROPRIETARY RIGHTS OF OTHERS.  INO SHALL NOT BE LIABLE TO ONCSD, ONCSD’S SUCCESSORS OR ASSIGNS OR ANY THIRD PARTY WITH RESPECT TO: ANY CLAIM ARISING FROM USE OF THE LICENSED TECHNOLOGY AND UNDER THIS AGREEMENT OR FROM THE MANUFACTURE, USE OR SALE OF THE LICENSED TECHNOLOGY; OR ANY CLAIM FOR LOSS OF PROFITS, LOSS OR INTERRUPTION OF BUSINESS, OR FOR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND.

 

8.4           EXCEPT AS SET FORTH IN SECTION 8.2, ALL TECHNOLOGY LICENSED UNDER THE ONCSD PATENT RIGHTS IN THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS AND ONCSD MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT THERETO.  BY WAY OF EXAMPLE, BUT NOT OF LIMITATION, ONCSD MAKES NO REPRESENTATIONS OR WARRANTIES (i) OF COMMERCIAL UTILITY; (ii) OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE; OR (iii) THAT THE USE OF THE LICENSED TECHNOLOGY UNDER THIS AGREEMENT WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADE SECRET OR

 

 

TRADEMARK OR OTHER PROPRIETARY RIGHTS OF OTHERS.  ONCSD SHALL NOT BE LIABLE TO INO, INO’S SUCCESSORS OR ASSIGNS OR ANY THIRD PARTY WITH RESPECT TO: ANY CLAIM ARISING FROM USE OF THE LICENSED TECHNOLOGY AND UNDER THIS AGREEMENT OR FROM THE MANUFACTURE, USE OR SALE OF THE LICENSED TECHNOLOGY; OR ANY CLAIM FOR LOSS OF PROFITS, LOSS OR INTERRUPTION OF BUSINESS, OR FOR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND.

 

8.5                                Indemnity

 

8.5.1                        ONCSD shall defend, indemnify and hold harmless INO, its trustees, officers, agents and employees (individually, an “ONCSD Indemnified Party”, and collectively, the “ONCSD Indemnified Parties”), from and against any and all liability, loss, damage, action, claim or expense suffered or incurred by the ONCSD Indemnified Parties (including attorney’s fees and expenses) (individually, a “Liability”, and collectively, the “Liabilities”) that results from or arises out of:  (a) the development, use, manufacture, promotion, sale or other disposition of any technology covered by the INO PATENT RIGHTS by ONCSD, its assignees, sublicensees, vendors or other third parties; (b) any breach by ONCSD of this AGREEMENT; and (c) the enforcement by a ONCSD Indemnified Party of this Section.  Without limiting the foregoing, ONCSD shall defend, indemnify and hold harmless the ONCSD Indemnified Parties from and against any Liabilities resulting from:

 

8.5.1.1 any product liability or other claim of any kind related to the use by a third party of a technology covered by the INO PATENT RIGHTS that was manufactured, sold or otherwise disposed by ONCSD, its assignees, sublicensees, or agents, other than such Liabilities arising from or related to the inaccuracy of any representation or warranty of INO in Section 8.1 of this AGREEMENT; and

 

8.5.1.2 a claim by a third party that the design, composition, manufacture, use, sale, or other disposition of any technology covered by the INO PATENT RIGHTS infringes or violates any patent, copyright, trademark or other intellectual property rights of such third party, except to the extent that any such claim may relate to the inaccuracy of any representation or warranty in Section 8.1; and

 

8.5.1.3 clinical trials or studies conducted by or on behalf of ONCSD and/or its sublicensees relating to the technology covered by the INO PATENT RIGHTS, including, without limitation, any claim by or on behalf of a human subject of any such clinical trial or study.

 

 

8.5.2                        INO shall defend, indemnify and hold harmless ONCSD, its trustees, officers, agents and employees (individually, an “INO Indemnified Party”, and collectively, the “INO Indemnified Parties”), from and against any and all liability, loss, damage, action, claim or expense suffered or incurred by the INO Indemnified Parties (including attorney’s fees and expenses) (individually, a “Liability”, and collectively, the “Liabilities”) that results from or arises out of:  (a) the development, use, manufacture, promotion, sale or other disposition of any technology covered by the ONCSD PATENT RIGHTS by INO, its assignees, sublicensees, vendors or other third parties; (b) any breach by INO of this AGREEMENT; and (c) the enforcement by a INO Indemnified Party of this Section.  Without limiting the foregoing, INO shall defend, indemnify and hold harmless the INO Indemnified Parties from and against any Liabilities resulting from:

 

8.5.2.1 any product liability or other claim of any kind related to the use by a third party of a technology covered by the ONCSD PATENT RIGHTS that was manufactured, sold or otherwise disposed by INO, its assignees, sublicensees, or agents, other than such Liabilities arising from or related to the inaccuracy of any representation or warranty of ONCSD in Section 8.2 of this AGREEMENT; and

 

8.5.2.2 a claim by a third party that the design, composition, manufacture, use, sale, or other disposition of any technology covered by the ONCSD PATENT RIGHTS infringes or violates any patent, copyright, trademark or other intellectual property rights of such third party, except to the extent that any such claim may relate to the inaccuracy of any representation or warranty in Section 8.2; and

 

8.5.2.3 clinical trials or studies conducted by or on behalf of INO and/or its sublicensees relating to the technology covered by the ONCSD PATENT RIGHTS, including, without limitation, any claim by or on behalf of a human subject of any such clinical trial or study.

 

8.6 ONCSD is not permitted to settle or compromise any claim or action giving rise to Liabilities in a manner that imposes any restrictions or obligations on INO or grants any rights to the INO PATENT RIGHTS without INO’s prior written consent.  If ONCSD fails or declines to assume the defense of any such claim or action within thirty (30) days after notice thereof, INO may assume the defense of such claim or action for the account and at the risk of ONCSD, and any Liabilities related thereto shall be conclusively deemed a liability of ONCSD.  The indemnification rights of the parties or any other Indemnified Party contained herein are in addition to all other rights which the parties or such Indemnified Party may have at law or in equity or otherwise.

 

Similarly, INO is not permitted to settle or compromise any claim or action giving rise to Liabilities in a manner that imposes any restrictions or obligations on ONCSD or grants any rights to the ONCSD PATENT RIGHTS without ONCSD’s prior written consent.  If INO fails or declines to assume the defense of any such claim or action within thirty (30) days after notice thereof, ONCSD may assume the defense of such claim or action for the account and at the risk of INO, and any Liabilities related thereto shall be conclusively deemed a liability of INO.  The indemnification rights of the parties or any other Indemnified Party contained herein are in addition to all other rights which the parties or such Indemnified Party may have at law or in equity or otherwise.

 

 

9.                                       USE OF INO’S NAME

 

9.1 ONCSD and its employees and agents shall not use, and ONCSD shall not permit its sublicensees to use, INO’s name or any adaptation thereof, or any INO seal, logotype, trademark, or service mark, or the name, mark, or logotype of any INO representative or organization in any way without the prior written consent of INO.

 

9.2 INO and its employees and agents shall not use, and INO shall not permit its sublicensees to use, ONCSD’s name or any adaptation thereof, or any ONCSD seal, logotype, trademark, or service mark, or the name, mark, or logotype of any ONCSD representative or organization in any way without the prior written consent of ONCSD.

 

10.                                 ADDITIONAL PROVISIONS

 

10.1                          Nothing in this AGREEMENT shall be deemed to establish a relationship of principal and agent between INO and ONCSD, or between or among any of either party’s agents or employees for any purpose whatsoever, nor shall this AGREEMENT be construed as creating any other form of legal association or arrangement which would impose liability upon one party for the act or failure to act on behalf of the other party.

 

10.2                          Either party is not permitted to assign this AGREEMENT or any part of it to any person or entity other than its AFFILIATE, either directly or by operation of law, without the prior written consent of the other party, in its sole discretion.  Any prohibited assignment of this AGREEMENT or the rights hereunder shall be null and void.  No assignment relieves a party of its responsibility for the performance of any accrued obligations, which it has prior to such assignment.

 

10.3                          A waiver by either party of a breach of any provision of this AGREEMENT will not constitute a waiver of any subsequent breach of that provision or a waiver of any breach of any other provision of this AGREEMENT.

 

10.4                          Notices, payments, statements, reports and other communications under this AGREEMENT shall be in writing and shall be deemed to have been received as of the day after the date sent if sent by public courier (e.g., Federal Express) or by Express Mail, receipt requested, and addressed as follows:

 

If for INO:                              Inovio Pharmaceuticals, Inc.

1787 Sentry Parkway West

Building 18, Suite 400

Blue Bell, PA 19422

 

Attention: J. Joseph Kim

 

 

If for ONCSD:

 

OncoSec Medical Inc.
 8th Floor - 200 South Virginia Street
 Reno NV 89501
 Attention:  Punit Dhillon
 Fax No.: 858-777-5481

 

with a copy to:
 Morrison Foerster

12531 High Bluff Drive, Suite 100

San Diego, CA 92130-2040

Attention: Steve Rowles

Fax No.: 858-720-5125

 

Either party may change its official address upon written notice to the other party and allow for ten (10) business days for the change to be effective.

 

10.5                          This AGREEMENT shall be construed and governed in accordance with the laws of the Commonwealth of Pennsylvania, without giving effect to conflict of law provisions.  In the event that a party to this AGREEMENT perceives the existence of a dispute with the other party concerning any right or duty provided for herein, the parties will, as soon as practicable, confer in an attempt to resolve the dispute.  If the parties are unable to resolve such dispute amicably, then the parties hereby submit to the exclusive jurisdiction of and venue in the courts located in the Eastern District of the Commonwealth of Pennsylvania with respect to any and all disputes concerning the subject of this AGREEMENT.

 

10.6                          INO and ONCSD shall not discriminate against any employee or applicant for employment because of race, color, sex, sexual or affectional preference, age, religion, national or ethnic origin, handicap, or because he or she is a disabled veteran or a veteran of the Vietnam Era.

 

10.7                          Each party agrees that it shall comply with all prevailing laws, rules and regulations that apply to its activities or obligations under this AGREEMENT.

 

10.8                          If any provision of this AGREEMENT shall be held to be illegal, invalid or unenforceable, then such illegality, invalidity or unenforceability shall attach only to such provision, and shall not in any manner affect or render illegal, invalid or unenforceable any other provision of this AGREEMENT, and this AGREEMENT shall be carried out as if any such illegal, invalid or unenforceable provision were not contained herein.

 

10.9                          This AGREEMENT, including the attachments expressly referred to herein and attached, embody the entire agreement and understanding among the parties hereto and thereto and supersede all prior agreements and understandings relating to the subject matter.  This AGREEMENT may not be changed, modified, extended or terminated except by written amendment executed by an authorized representative of each party.

 

 

10.10                     All agreements, covenants, indemnities, obligations, rights, licenses, options, representations, and warranties set forth in this AGREEMENT or accrued prior to Termination or Expiration of this AGREEMENT will survive the execution, delivery, Termination, or Expiration of this AGREEMENT and remain in full effect, unless expressly provided otherwise herein.

 

[SIGNATURES BY PARTIES ON FOLLOWING PAGE]

 

 

IN WITNESS WHEREOF, the parties, intending to be legally bound, have caused this AGREEMENT to be executed by their duly-authorized representatives.

 

 

	
INOVIO PHARMACEUTICALS, INC.
    	
 
    	
ONCOSEC   MEDICAL INCORPORATED
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:  J.   Joseph Kim
    	
 
    	
By:   Punit Dhillon
    
	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
/s/J.   Joseph Kim
    	
 
    	
Name:
    	
/s/Punit   Dhillon
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
President   and CEO
    	
 
    	
Title:
    	
President   and CEO
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
March 24,   2011
    	
 
    	
Date:   
    	
March 24,   2011
    

 

 

APPENDIX A

 

	
Inovio Ref #
    	
 
    	
Cntry
    	
 
    	
Type
    	
 
    	
Status
    	
 
    	
Serial No.
    	
 
    	
Filing Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
GRANTED
    	
 
    	
08/46756
    	
 
    	
6-Jun-95
    	
 
    	
5702359
    	
 
    	
30-Dec-97
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
US
    	
 
    	
CON
    	
 
    	
GRANTED
    	
 
    	
09/427151
    	
 
    	
25-Oct-99
    	
 
    	
6451002
    	
 
    	
17-Sep-02
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
US
    	
 
    	
CON
    	
 
    	
GRANTED
    	
 
    	
10/053861
    	
 
    	
17-Jan-02
    	
 
    	
6567694
    	
 
    	
20-May-03
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
US
    	
 
    	
DIV
    	
 
    	
GRANTED
    	
 
    	
09/551327
    	
 
    	
18-Apr-00
    	
 
    	
6418341
    	
 
    	
9-Jul-02
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
US
    	
 
    	
REX
    	
 
    	
GRANTED
    	
 
    	
90/005590
    	
 
    	
15-Dec-99
    	
 
    	
5702359C1
    	
 
    	
28-Mar-06
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
US
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
08/930168
    	
 
    	
10-Apr-95
    	
 
    	
5810762
    	
 
    	
22-Sep-98
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
US
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
08/042039
    	
 
    	
1-Apr-93
    	
 
    	
5439440
    	
 
    	
8-Aug-95
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
GRANTED
    	
 
    	
08/537265
    	
 
    	
29-Sep-95
    	
 
    	
5993434
    	
 
    	
30-Nov-99
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
US
    	
 
    	
CON
    	
 
    	
GRANTED
    	
 
    	
10/177560
    	
 
    	
21-Jun-02
    	
 
    	
6569149
    	
 
    	
27-May-03
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
US
    	
 
    	
CON
    	
 
    	
GRANTED
    	
 
    	
10/213514
    	
 
    	
6-Aug-02
    	
 
    	
6763264
    	
 
    	
13-Jul-04
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
MX
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
PA/A/1997/006929
    	
 
    	
10-Apr-95
    	
 
    	
218786
    	
 
    	
21-Jan-04
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
MX
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
PA/A/1997/008316
    	
 
    	
22-May-96
    	
 
    	
248023
    	
 
    	
13-Aug-07
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
KR
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
706014/97
    	
 
    	
10-Apr-95
    	
 
    	
247255
    	
 
    	
10-Dec-99
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
KR
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
708424/97
    	
 
    	
22-May-96
    	
 
    	
260238
    	
 
    	
4-Apr-00
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
JP
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
530968/96
    	
 
    	
10-Apr-95
    	
 
    	
3338880
    	
 
    	
16-Aug-02
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
GB
    	
 
    	
EDV
    	
 
    	
GRANTED
    	
 
    	
02008920.7
    	
 
    	
10-Apr-95
    	
 
    	
1240917
    	
 
    	
23-Jun-04
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
GB
    	
 
    	
EPC
    	
 
    	
GRANTED
    	
 
    	
96916550.5
    	
 
    	
22-May-96
    	
 
    	
0874663
    	
 
    	
29-Sep-99
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
FR
    	
 
    	
EDV
    	
 
    	
GRANTED
    	
 
    	
02008920.7
    	
 
    	
10-Apr-95
    	
 
    	
1240917
    	
 
    	
23-Jun-04
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
FR
    	
 
    	
EPC
    	
 
    	
GRANTED
    	
 
    	
96916550.5
    	
 
    	
22-May-96
    	
 
    	
0874663
    	
 
    	
29-Sep-99
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
EP
    	
 
    	
DIV
    	
 
    	
GRANTED
    	
 
    	
02008920.7
    	
 
    	
10-Apr-95
    	
 
    	
1240917
    	
 
    	
23-Jun-04
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
EP
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
96916550.5
    	
 
    	
22-May-96
    	
 
    	
0874663
    	
 
    	
29-Sep-99
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
DE
    	
 
    	
EDV
    	
 
    	
GRANTED
    	
 
    	
02008920.7
    	
 
    	
10-Apr-95
    	
 
    	
1240917
    	
 
    	
23-Jun-04
    

 

 

	
GTI-1160
    	
 
    	
DE
    	
 
    	
EPC
    	
 
    	
GRANTED
    	
 
    	
96916550.5
    	
 
    	
22-May-96
    	
 
    	
69604509.5
    	
 
    	
29-Sep-99
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
CN
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
96194608.3
    	
 
    	
22-May-96
    	
 
    	
ZL96194608.3
    	
 
    	
26-May-04
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
CA
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
2216131
    	
 
    	
10-Apr-95
    	
 
    	
2216131
    	
 
    	
5-Feb-02
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1160
    	
 
    	
CA
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
2218255
    	
 
    	
22-May-96
    	
 
    	
2218255
    	
 
    	
20-Nov-01
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
ZA
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
98/7596
    	
 
    	
21-Aug-98
    	
 
    	
98/7596
    	
 
    	
31-Aug-99
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
GRANTED
    	
 
    	
09/177678
    	
 
    	
22-Oct-98
    	
 
    	
6241701
    	
 
    	
5-Jun-01
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
US
    	
 
    	
CON
    	
 
    	
GRANTED
    	
 
    	
09/861016
    	
 
    	
18-May-01
    	
 
    	
6516223
    	
 
    	
4-Feb-03
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
US
    	
 
    	
DIV
    	
 
    	
GRANTED
    	
 
    	
09/189062
    	
 
    	
9-Nov-98
    	
 
    	
6233482
    	
 
    	
15-May-01
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
US
    	
 
    	
DIV
    	
 
    	
GRANTED
    	
 
    	
09/189360
    	
 
    	
9-Nov-98
    	
 
    	
6181964
    	
 
    	
30-Jan-01
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
US
    	
 
    	
DIV
    	
 
    	
GRANTED
    	
 
    	
09/189070
    	
 
    	
9-Nov-98
    	
 
    	
6068650
    	
 
    	
30-May-00
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
US
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
08/905240
    	
 
    	
1-Aug-97
    	
 
    	
6055453
    	
 
    	
25-Apr-00
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
US
    	
 
    	
CON
    	
 
    	
GRANTED
    	
 
    	
09/900601
    	
 
    	
5-Jul-01
    	
 
    	
7412284
    	
 
    	
12-Aug-08
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
US
    	
 
    	
DIV
    	
 
    	
GRANTED
    	
 
    	
09/227417
    	
 
    	
8-Jan-99
    	
 
    	
6216034
    	
 
    	
10-Apr-01
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
US
    	
 
    	
DIV
    	
 
    	
GRANTED
    	
 
    	
09/227416
    	
 
    	
8-Jan-99
    	
 
    	
6014584
    	
 
    	
11-Jan-00
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
KR
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
10-1999-7002781
    	
 
    	
31-Jul-98
    	
 
    	
756252
    	
 
    	
31-Aug-07
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
JP
    	
 
    	
DIV
    	
 
    	
GRANTED
    	
 
    	
2002-57679
    	
 
    	
31-Jul-98
    	
 
    	
4180285
    	
 
    	
5-Sep-08
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
HK
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
00106147.9
    	
 
    	
31-Jul-98
    	
 
    	
1027049
    	
 
    	
28-Apr-06
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
CN
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
98801461.0
    	
 
    	
31-Jul-98
    	
 
    	
98801461.0
    	
 
    	
7-Sep-05
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
CN-2
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
200510084733.9
    	
 
    	
31-Jul-98
    	
 
    	
1768873
    	
 
    	
28-Jan-11
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
CA
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
2268026
    	
 
    	
31-Jul-98
    	
 
    	
2268026
    	
 
    	
29-Jul-03
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
AU
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
86823/98
    	
 
    	
31-Jul-98
    	
 
    	
734343
    	
 
    	
27-Sep-01
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
AU
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
17074/00
    	
 
    	
21-Oct-99
    	
 
    	
767814
    	
 
    	
11-Mar-04
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
AR
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
P990105331
    	
 
    	
21-Oct-99
    	
 
    	
AR020932B1
    	
 
    	
30-May-06
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
EP
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
98938256.9
    	
 
    	
31-Jul-98
    	
 
    	
999867
    	
 
    	
08-Sep-2010
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
DE
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
98938256.9
    	
 
    	
31-Jul-98
    	
 
    	
999867
    	
 
    	
08-Sep-2010
    

 

 

	
GTI-1200
    	
 
    	
FR
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
98938256.9
    	
 
    	
31-Jul-98
    	
 
    	
999867
    	
 
    	
08-Sep-2010
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
GB
    	
 
    	
PCT
    	
 
    	
GRANTED
    	
 
    	
98938256.9
    	
 
    	
31-Jul-98
    	
 
    	
999867
    	
 
    	
08-Sep-2010
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1200
    	
 
    	
CN
    	
 
    	
DIV
    	
 
    	
GRANTED
    	
 
    	
200510084733.9
    	
 
    	
31-Jul-98
    	
 
    	
1768873
    	
 
    	
28-Jan-2011
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1360
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
GRANTED
    	
 
    	
10/339708
    	
 
    	
8-Jan-03
    	
 
    	
7171264
    	
 
    	
30-Jan-07
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1360
    	
 
    	
US
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
09/567404
    	
 
    	
8-May-00
    	
 
    	
6520950
    	
 
    	
18-Feb-03
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1250
    	
 
    	
US
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6120493
    	
 
    	
19-Sep-2000
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1250
    	
 
    	
US
    	
 
    	
CON
    	
 
    	
GRANTED
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6208893
    	
 
    	
27-Mar-2001
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1110
    	
 
    	
US
    	
 
    	
CON
    	
 
    	
GRANTED
    	
 
    	
 
    	
 
    	
 
    	
 
    	
7181271
    	
 
    	
20-Feb-2007
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1230
    	
 
    	
US
    	
 
    	
CON
    	
 
    	
GRANTED
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6865416
    	
 
    	
08-Mar-2005
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1230
    	
 
    	
US
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6347247
    	
 
    	
12-Feb-2002
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1230
    	
 
    	
EP
    	
 
    	
 
    	
 
    	
PENDING
    	
 
    	
99922830.7
    	
 
    	
07-May-1999
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1250
    	
 
    	
US
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6009347
    	
 
    	
28-Dec-1999
    

 

 

APPENDIX B

 

	
Inovio Ref #
    	
 
    	
Cntry
    	
 
    	
Type
    	
 
    	
Status
    	
 
    	
Serial No.
    	
 
    	
Filing Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1130
    	
 
    	
AU
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
49883/99
    	
 
    	
13-Jul-1999
    	
 
    	
770092
    	
 
    	
27-May-2004
    
	
GTI-1130
    	
 
    	
CA
    	
 
    	
PCT
    	
 
    	
Published
    	
 
    	
2337652
    	
 
    	
13-Jul-1999
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1130
    	
 
    	
EP
    	
 
    	
PCT
    	
 
    	
Published
    	
 
    	
99933937.7
    	
 
    	
13-Jul-1999
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1130
    	
 
    	
US
    	
 
    	
ORD
    	
 
    	
Granted
    	
 
    	
09/352809
    	
 
    	
13-Jul-1999
    	
 
    	
6697669
    	
 
    	
24-Feb-2004
    
	
GTI-1130
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
Granted
    	
 
    	
10/165657
    	
 
    	
07-Jun-2002
    	
 
    	
6678556
    	
 
    	
13-Jan-2004
    
	
GTI-1130
    	
 
    	
US
    	
 
    	
CON
    	
 
    	
Granted
    	
 
    	
10/756946
    	
 
    	
13-Jan-2004
    	
 
    	
7570992
    	
 
    	
04-Aug-2009
    
	
GTI-1130
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
Granted
    	
 
    	
09/625825
    	
 
    	
26-Jul-2000
    	
 
    	
6654636
    	
 
    	
25-Nov-2003
    
	
GTI-1130
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
Granted
    	
 
    	
10/233007
    	
 
    	
30-Aug-2002
    	
 
    	
6972013
    	
 
    	
06-Dec-2005
    
	
GTI-1130
    	
 
    	
US
    	
 
    	
CON
    	
 
    	
Published
    	
 
    	
11/291459
    	
 
    	
30-Nov-2005
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1370
    	
 
    	
AU
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
41771/00
    	
 
    	
23-Mar-2000
    	
 
    	
778736
    	
 
    	
14-Apr-2005
    
	
GTI-1370
    	
 
    	
EP
    	
 
    	
PCT
    	
 
    	
Published
    	
 
    	
00921451.1
    	
 
    	
23-Mar-2000
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1370
    	
 
    	
TW
    	
 
    	
ORD
    	
 
    	
Granted
    	
 
    	
89105497
    	
 
    	
11-Apr-2000
    	
 
    	
NI-153798
    	
 
    	
06-Aug-2002
    
	
GTI-1370
    	
 
    	
US
    	
 
    	
DIV
    	
 
    	
Granted
    	
 
    	
10/215963
    	
 
    	
08-Aug-2002
    	
 
    	
7054685
    	
 
    	
30-May-2006
    
	
GTI-1370
    	
 
    	
US
    	
 
    	
ORD
    	
 
    	
Granted
    	
 
    	
09/535683
    	
 
    	
23-Mar-2000
    	
 
    	
6678558
    	
 
    	
13-Jan-2004
    
	
GTI-1530
    	
 
    	
AT
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
99966432.9
    	
 
    	
17-Dec-1999
    	
 
    	
1140283
    	
 
    	
08-Mar-2006
    
	
GTI-1530
    	
 
    	
AU
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
14354/95
    	
 
    	
13-Dec-1994
    	
 
    	
691237
    	
 
    	
27-Aug-1998
    
	
GTI-1530
    	
 
    	
AU
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
68821/98
    	
 
    	
02-Apr-1998
    	
 
    	
741399
    	
 
    	
14-Mar-2002
    
	
GTI-1530
    	
 
    	
AU
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
21969/00
    	
 
    	
17-Dec-1999
    	
 
    	
763535
    	
 
    	
06-Nov-2003
    
	
GTI-1530
    	
 
    	
CA
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
2185024
    	
 
    	
13-Dec-1994
    	
 
    	
2185024
    	
 
    	
08-May-2001
    
	
GTI-1530
    	
 
    	
CA
    	
 
    	
PCT
    	
 
    	
Published
    	
 
    	
2311474
    	
 
    	
02-Apr-1998
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1530
    	
 
    	
CH
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
99966432.9
    	
 
    	
17-Dec-1999
    	
 
    	
1140283
    	
 
    	
08-Mar-2006
    
	
GTI-1530
    	
 
    	
DE
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
95905926.2
    	
 
    	
13-Dec-1994
    	
 
    	
P69426210.2
    	
 
    	
25-Oct-2000
    
	
GTI-1530
    	
 
    	
DE
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98914475.3
    	
 
    	
02-Apr-1998
    	
 
    	
69806794.0
    	
 
    	
24-Jul-2002
    
	
GTI-1530
    	
 
    	
DE
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
99966432.9
    	
 
    	
17-Dec-1999
    	
 
    	
1140283
    	
 
    	
08-Mar-2006
    
	
GTI-1530
    	
 
    	
EP
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
95905926.2
    	
 
    	
13-Dec-1994
    	
 
    	
0751802
    	
 
    	
25-Oct-2000
    
	
GTI-1530
    	
 
    	
EP
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
98914475.3
    	
 
    	
02-Apr-1998
    	
 
    	
1028777
    	
 
    	
24-Jul-2002
    
	
GTI-1530
    	
 
    	
EP
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
99966432.9
    	
 
    	
17-Dec-1999
    	
 
    	
1140283
    	
 
    	
08-Mar-2006
    

 

 

	
GTI-1530
    	
 
    	
ES
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
99966432.9
    	
 
    	
17-Dec-1999
    	
 
    	
1140283
    	
 
    	
08-Mar-2006
    
	
GTI-1530
    	
 
    	
FR
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
95905926.2
    	
 
    	
13-Dec-1994
    	
 
    	
0751802
    	
 
    	
25-Oct-2000
    
	
GTI-1530
    	
 
    	
FR
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98914475.3
    	
 
    	
02-Apr-1998
    	
 
    	
1028777
    	
 
    	
24-Jul-2002
    
	
GTI-1530
    	
 
    	
FR
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
99966432.9
    	
 
    	
17-Dec-1999
    	
 
    	
1140283
    	
 
    	
08-Mar-2006
    
	
GTI-1530
    	
 
    	
GB
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
95905926.2
    	
 
    	
13-Dec-1994
    	
 
    	
0751802
    	
 
    	
25-Oct-2000
    
	
GTI-1530
    	
 
    	
GB
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98914475.3
    	
 
    	
02-Apr-1998
    	
 
    	
1028777
    	
 
    	
24-Jul-2002
    
	
GTI-1530
    	
 
    	
GB
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
99966432.9
    	
 
    	
17-Dec-1999
    	
 
    	
1140283
    	
 
    	
08-Mar-2006
    
	
GTI-1530
    	
 
    	
IT
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
95905926.2
    	
 
    	
13-Dec-1994
    	
 
    	
0751802
    	
 
    	
25-Oct-2000
    
	
GTI-1530
    	
 
    	
IT
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
99966432.9
    	
 
    	
17-Dec-1999
    	
 
    	
1140283
    	
 
    	
08-Mar-2006
    
	
GTI-1530
    	
 
    	
JP
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
525651/95
    	
 
    	
13-Dec-1994
    	
 
    	
3554935
    	
 
    	
21-May-2004
    
	
GTI-1530
    	
 
    	
NL
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
99966432.9
    	
 
    	
17-Dec-1999
    	
 
    	
1140283
    	
 
    	
08-Mar-2006
    
	
GTI-1530
    	
 
    	
TW
    	
 
    	
ORD
    	
 
    	
Granted
    	
 
    	
87106879
    	
 
    	
05-May-1998
    	
 
    	
NI-108036
    	
 
    	
01-Sep-1999
    
	
GTI-1530
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
Granted
    	
 
    	
08/219970
    	
 
    	
30-Mar-1994
    	
 
    	
5462520
    	
 
    	
31-Oct-1995
    
	
GTI-1530
    	
 
    	
US
    	
 
    	
ORD
    	
 
    	
Granted
    	
 
    	
07/931061
    	
 
    	
17-Aug-1992
    	
 
    	
5318514
    	
 
    	
07-Jun-1994
    
	
GTI-1530
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
Granted
    	
 
    	
08/310647
    	
 
    	
22-Sep-1994
    	
 
    	
5464386
    	
 
    	
07-Nov-1995
    
	
GTI-1530
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
Granted
    	
 
    	
08/552200
    	
 
    	
02-Nov-1995
    	
 
    	
5688233
    	
 
    	
18-Nov-1997
    
	
GTI-1530
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
Granted
    	
 
    	
08/964436
    	
 
    	
04-Nov-1997
    	
 
    	
6009345
    	
 
    	
28-Dec-1999
    
	
GTI-1530
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
Granted
    	
 
    	
09/213782
    	
 
    	
17-Dec-1998
    	
 
    	
5968006
    	
 
    	
19-Oct-1999
    
	
GTI-1540
    	
 
    	
DE
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
95925349.3
    	
 
    	
27-Jun-1995
    	
 
    	
69502733.6
    	
 
    	
27-May-1998
    
	
GTI-1540
    	
 
    	
EP
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
95925349.3
    	
 
    	
27-Jun-1995
    	
 
    	
0788392
    	
 
    	
27-May-1998
    
	
GTI-1540
    	
 
    	
GB
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
95925349.3
    	
 
    	
27-Jun-1995
    	
 
    	
0788392
    	
 
    	
27-May-1998
    
	
GTI-1540
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
Granted
    	
 
    	
08/328895
    	
 
    	
25-Oct-1994
    	
 
    	
6132419
    	
 
    	
17-Oct-2000
    
	
GTI-1540
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
Granted
    	
 
    	
08/304584
    	
 
    	
12-Sep-1994
    	
 
    	
5501662
    	
 
    	
26-Mar-1996
    
	
GTI-2010
    	
 
    	
AU
    	
 
    	
PCT
    	
 
    	
Pending
    	
 
    	
PCT/US2009/000273
    	
 
    	
28-Jun-2010
    	
 
    	
 
    	
 
    	
 
    
	
GTI-2010
    	
 
    	
CA
    	
 
    	
PCT
    	
 
    	
Pending
    	
 
    	
2710408
    	
 
    	
21-Jun-2010
    	
 
    	
 
    	
 
    	
 
    
	
GTI-2010
    	
 
    	
CN
    	
 
    	
PCT
    	
 
    	
Pending
    	
 
    	
PCT/US2009/000273
    	
 
    	
23-Jul-2010
    	
 
    	
 
    	
 
    	
 
    
	
GTI-2010
    	
 
    	
EP
    	
 
    	
PCT
    	
 
    	
Pending
    	
 
    	
09702445.9
    	
 
    	
16-Jan-2009
    	
 
    	
 
    	
 
    	
 
    
	
GTI-2010
    	
 
    	
IN
    	
 
    	
PCT
    	
 
    	
Pending
    	
 
    	
4726/DELNP/2010
    	
 
    	
30-Jun-2010
    	
 
    	
 
    	
 
    	
 
    
	
GTI-2010
    	
 
    	
JP
    	
 
    	
PCT
    	
 
    	
Pending
    	
 
    	
PCT/US2009/000273
    	
 
    	
15-Jul-2010
    	
 
    	
 
    	
 
    	
 
    
	
GTI-2010
    	
 
    	
KR
    	
 
    	
PCT
    	
 
    	
Pending
    	
 
    	
10-2010-7018104
    	
 
    	
16-Aug-2010
    	
 
    	
 
    	
 
    	
 
    
	
GTI-2010
    	
 
    	
US
    	
 
    	
ORD
    	
 
    	
Pending
    	
 
    	
12836163
    	
 
    	
14-Jul-2010
    	
 
    	
 
    	
 
    	
 
    

 

 

	
GTI-2010
    	
 
    	
WO
    	
 
    	
ORD
    	
 
    	
Published
    	
 
    	
PCT/US2009/000273
    	
 
    	
16-Jan-2009
    	
 
    	
 
    	
 
    	
 
    
	
GTI-5000
    	
 
    	
AT
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98909691.2
    	
 
    	
03-Apr-1998
    	
 
    	
1023107
    	
 
    	
30-Aug-2006
    
	
GTI-5000
    	
 
    	
AU
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
69906/98
    	
 
    	
03-Apr-1998
    	
 
    	
733628
    	
 
    	
30-Aug-2001
    
	
GTI-5000
    	
 
    	
BE
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98909691.2
    	
 
    	
03-Apr-1998
    	
 
    	
1023107
    	
 
    	
30-Aug-2006
    
	
GTI-5000
    	
 
    	
CA
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
2285056
    	
 
    	
03-Apr-1998
    	
 
    	
2285056
    	
 
    	
14-Dec-2004
    
	
GTI-5000
    	
 
    	
CH
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98909691.2
    	
 
    	
03-Apr-1998
    	
 
    	
1023107
    	
 
    	
30-Aug-2006
    
	
GTI-5000
    	
 
    	
CN
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
98803980.X
    	
 
    	
03-Apr-1998
    	
 
    	
ZL98803980.X
    	
 
    	
24-Apr-2006
    
	
GTI-5000
    	
 
    	
DE
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98909691.2
    	
 
    	
03-Apr-1998
    	
 
    	
DE69835761.2-08
    	
 
    	
30-Aug-2006
    
	
GTI-5000
    	
 
    	
DK
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98909691.2
    	
 
    	
03-Apr-1998
    	
 
    	
1023107
    	
 
    	
30-Aug-2006
    
	
GTI-5000
    	
 
    	
EA
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
199900882
    	
 
    	
03-Apr-1998
    	
 
    	
002087
    	
 
    	
24-Dec-2001
    
	
GTI-5000
    	
 
    	
EP
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
98909691.2
    	
 
    	
03-Apr-1998
    	
 
    	
1023107
    	
 
    	
30-Aug-2006
    
	
GTI-5000
    	
 
    	
ES
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98909691.2
    	
 
    	
03-Apr-1998
    	
 
    	
1023107
    	
 
    	
30-Aug-2006
    
	
GTI-5000
    	
 
    	
FR
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98909691.2
    	
 
    	
03-Apr-1998
    	
 
    	
1023107
    	
 
    	
30-Aug-2006
    
	
GTI-5000
    	
 
    	
GB
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98909691.2
    	
 
    	
03-Apr-1998
    	
 
    	
1023107
    	
 
    	
30-Aug-2006
    
	
GTI-5000
    	
 
    	
IE
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98909691.2
    	
 
    	
03-Apr-1998
    	
 
    	
1023107
    	
 
    	
30-Aug-2006
    
	
GTI-5000
    	
 
    	
IT
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98909691.2
    	
 
    	
03-Apr-1998
    	
 
    	
1023107
    	
 
    	
30-Aug-2006
    
	
GTI-5000
    	
 
    	
KR
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
1999-7009009
    	
 
    	
03-Apr-1998
    	
 
    	
427786
    	
 
    	
07-Apr-2004
    
	
GTI-5000
    	
 
    	
KZ
    	
 
    	
EUC
    	
 
    	
Granted
    	
 
    	
199900882
    	
 
    	
03-Apr-1998
    	
 
    	
2087
    	
 
    	
24-Dec-2001
    
	
GTI-5000
    	
 
    	
LU
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98909691.2
    	
 
    	
03-Apr-1998
    	
 
    	
1023107
    	
 
    	
30-Aug-2006
    
	
GTI-5000
    	
 
    	
MX
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
999026
    	
 
    	
03-Apr-1998
    	
 
    	
253159
    	
 
    	
09-Jan-2008
    
	
GTI-5000
    	
 
    	
NL
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98909691.2
    	
 
    	
03-Apr-1998
    	
 
    	
1023107
    	
 
    	
30-Aug-2006
    
	
GTI-5000
    	
 
    	
NO
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
19994820
    	
 
    	
03-Apr-1998
    	
 
    	
327806
    	
 
    	
28-Sep-2009
    
	
GTI-5000
    	
 
    	
NZ
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
337853
    	
 
    	
03-Apr-1998
    	
 
    	
337853
    	
 
    	
08-Jul-2002
    
	
GTI-5000
    	
 
    	
RU
    	
 
    	
EUC
    	
 
    	
Granted
    	
 
    	
199900882
    	
 
    	
03-Apr-1998
    	
 
    	
2087
    	
 
    	
24-Dec-2001
    
	
GTI-5000
    	
 
    	
SE
    	
 
    	
EPC
    	
 
    	
Granted
    	
 
    	
98909691.2
    	
 
    	
03-Apr-1998
    	
 
    	
1023107
    	
 
    	
30-Aug-2006
    
	
GTI-5000
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
Granted
    	
 
    	
09/565140
    	
 
    	
05-May-2000
    	
 
    	
6261281
    	
 
    	
17-Jul-2001
    
	
GTI-5000
    	
 
    	
US
    	
 
    	
ORD
    	
 
    	
Granted
    	
 
    	
09/055084
    	
 
    	
03-Apr-1998
    	
 
    	
6110161
    	
 
    	
29-Aug-2000
    
	
GTI-5000
    	
 
    	
US
    	
 
    	
CON
    	
 
    	
Granted
    	
 
    	
10/141561
    	
 
    	
07-May-2002
    	
 
    	
6610044
    	
 
    	
26-Aug-2003
    
	
GTI-5000
    	
 
    	
US
    	
 
    	
CON
    	
 
    	
Granted
    	
 
    	
10/620271
    	
 
    	
14-Jul-2003
    	
 
    	
6958060
    	
 
    	
25-Oct-2005
    
	
GTI-5000
    	
 
    	
US
    	
 
    	
ORD
    	
 
    	
Allowed
    	
 
    	
12/070233
    	
 
    	
15-Feb-2008
    	
 
    	
 
    	
 
    	
 
    
	
GTI-5001
    	
 
    	
AU
    	
 
    	
DIV
    	
 
    	
Pending
    	
 
    	
2009202678
    	
 
    	
01-Jul-2009
    	
 
    	
 
    	
 
    	
 
    

 

 

	
GTI-5001
    	
 
    	
CA
    	
 
    	
PCT
    	
 
    	
Published
    	
 
    	
2491000
    	
 
    	
04-Jul-2003
    	
 
    	
 
    	
 
    	
 
    
	
GTI-5001
    	
 
    	
CN
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
03820724.9
    	
 
    	
04-Jul-2003
    	
 
    	
03820724.9
    	
 
    	
28-Apr-2010
    
	
GTI-5001
    	
 
    	
EA
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
200401558
    	
 
    	
04-Jul-2003
    	
 
    	
009203
    	
 
    	
28-Dec-2007
    
	
GTI-5001
    	
 
    	
EP
    	
 
    	
PCT
    	
 
    	
Published
    	
 
    	
03762794.0
    	
 
    	
04-Jul-2003
    	
 
    	
 
    	
 
    	
 
    
	
GTI-5001
    	
 
    	
HK
    	
 
    	
PCT
    	
 
    	
Published
    	
 
    	
05108751.7
    	
 
    	
04-Jul-2003
    	
 
    	
 
    	
 
    	
 
    
	
GTI-5001
    	
 
    	
IN
    	
 
    	
PCT
    	
 
    	
Pending
    	
 
    	
4137/DELNP/2004
    	
 
    	
04-Jul-2003
    	
 
    	
 
    	
 
    	
 
    
	
GTI-5001
    	
 
    	
JP
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
2004-518966
    	
 
    	
04-Jul-2003
    	
 
    	
4461012
    	
 
    	
19-Feb-2010
    
	
GTI-5001
    	
 
    	
JP
    	
 
    	
DIV
    	
 
    	
Published
    	
 
    	
2009-279074
    	
 
    	
09-Dec-2009
    	
 
    	
 
    	
 
    	
 
    
	
GTI-5001
    	
 
    	
MX
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
PA/A/2005/000155
    	
 
    	
04-Jul-2003
    	
 
    	
277428
    	
 
    	
21-Jul-2010
    
	
GTI-5001
    	
 
    	
NZ
    	
 
    	
DIV
    	
 
    	
Granted
    	
 
    	
562306
    	
 
    	
04-Jul-2003
    	
 
    	
562306
    	
 
    	
08-Oct-2009
    
	
GTI-5001
    	
 
    	
NZ
    	
 
    	
DIV
    	
 
    	
Granted
    	
 
    	
566578
    	
 
    	
04-Jul-2003
    	
 
    	
566578
    	
 
    	
12-Nov-2009
    
	
GTI-5001
    	
 
    	
RU
    	
 
    	
EUC
    	
 
    	
Granted
    	
 
    	
200401558
    	
 
    	
04-Jul-2003
    	
 
    	
9203
    	
 
    	
28-Dec-2007
    
	
GTI-5001
    	
 
    	
US
    	
 
    	
ORD
    	
 
    	
Granted
    	
 
    	
10/612304
    	
 
    	
03-Jul-2003
    	
 
    	
7328064
    	
 
    	
05-Feb-2008
    
	
GTI-5001
    	
 
    	
US
    	
 
    	
CON
    	
 
    	
Published
    	
 
    	
11/985825
    	
 
    	
16-Nov-2007
    	
 
    	
 
    	
 
    	
 
    
	
GTI-5001
    	
 
    	
ZA
    	
 
    	
PCT
    	
 
    	
Granted
    	
 
    	
2005/0058
    	
 
    	
04-Jul-2003
    	
 
    	
2005/0058
    	
 
    	
29-Mar-2006
    
	
GTI-7001
    	
 
    	
AU
    	
 
    	
PCT
    	
 
    	
Pending
    	
 
    	
2007215263
    	
 
    	
09-Feb-2007
    	
 
    	
 
    	
 
    	
 
    
	
GTI-7001
    	
 
    	
CA
    	
 
    	
PCT
    	
 
    	
Published
    	
 
    	
2635437
    	
 
    	
09-Feb-2007
    	
 
    	
 
    	
 
    	
 
    
	
GTI-7001
    	
 
    	
CA
    	
 
    	
ORD
    	
 
    	
Pending
    	
 
    	
2686855
    	
 
    	
16-May-2008
    	
 
    	
 
    	
 
    	
 
    
	
GTI-7001
    	
 
    	
CN
    	
 
    	
PCT
    	
 
    	
Pending
    	
 
    	
200780002313.9
    	
 
    	
09-Feb-2007
    	
 
    	
 
    	
 
    	
 
    
	
GTI-7001
    	
 
    	
EP
    	
 
    	
PCT
    	
 
    	
Published
    	
 
    	
07750450.4
    	
 
    	
09-Feb-2007
    	
 
    	
 
    	
 
    	
 
    
	
GTI-7001
    	
 
    	
EP
    	
 
    	
ORD
    	
 
    	
Published
    	
 
    	
08767759.7
    	
 
    	
20-Nov-2009
    	
 
    	
 
    	
 
    	
 
    
	
GTI-7001
    	
 
    	
IN
    	
 
    	
PCT
    	
 
    	
Pending
    	
 
    	
6100/DELNP/2008
    	
 
    	
11-Jul-2008
    	
 
    	
 
    	
 
    	
 
    
	
GTI-7001
    	
 
    	
JP
    	
 
    	
PCT
    	
 
    	
Published
    	
 
    	
2008-554405
    	
 
    	
09-Feb-2007
    	
 
    	
 
    	
 
    	
 
    
	
GTI-7001
    	
 
    	
KR
    	
 
    	
PCT
    	
 
    	
Published
    	
 
    	
7019463/2008
    	
 
    	
09-Feb-2007
    	
 
    	
 
    	
 
    	
 
    
	
GTI-7001
    	
 
    	
MX
    	
 
    	
PCT
    	
 
    	
Pending
    	
 
    	
MX/A/2008/008981
    	
 
    	
09-Feb-2007
    	
 
    	
 
    	
 
    	
 
    
	
GTI-7001
    	
 
    	
NO
    	
 
    	
PCT
    	
 
    	
Pending
    	
 
    	
20083811
    	
 
    	
09-Feb-2007
    	
 
    	
 
    	
 
    	
 
    
	
GTI-7001
    	
 
    	
US
    	
 
    	
ORD
    	
 
    	
Published
    	
 
    	
11/704591
    	
 
    	
09-Feb-2007
    	
 
    	
 
    	
 
    	
 
    
	
GTI-7001
    	
 
    	
US
    	
 
    	
CIP
    	
 
    	
Published
    	
 
    	
11/894653
    	
 
    	
20-Aug-2007
    	
 
    	
 
    	
 
    	
 
    
	
GTI-7001
    	
 
    	
WO
    	
 
    	
ORD
    	
 
    	
Published
    	
 
    	
PCT/US2008/006311
    	
 
    	
16-May-2008
    	
 
    	
 
    	
 
    	
 
    
	
GTI-1220
    	
 
    	
US
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6027488
    	
 
    	
22-Feb-00
    
	
GTI-1220
    	
 
    	
US
    	
 
    	
DIV
    	
 
    	
GRANTED
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6746441
    	
 
    	
08-Jun-04
    
	
GTI-1590
    	
 
    	
US
    	
 
    	
ORD
    	
 
    	
GRANTED
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6192270
    	
 
    	
20-Feb-01
    
	
GTI-1560
    	
 
    	
US
    	
 
    	
ORD
    	
 
    	
GRANTED
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6150148
    	
 
    	
21-Nov-00
    

 

 

	
Inovio Ref #
    	
 
    	
Cntry
    	
 
    	
Type
    	
 
    	
Status
    	
 
    	
Publication
    	
 
    	
Filing Date
    	
 
    	
Patent No.
    	
 
    	
Issue Date
    
	
 
    	
 
    	
US
    	
 
    	
ORD
    	
 
    	
GRANTED
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6528315
    	
 
    	
4-Mar-03
    
	
 
    	
 
    	
PCT
    	
 
    	
 
    	
 
    	
 
    	
 
    	
WO 99/01157
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
EP
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/01157
    	
 
    	
 
    	
 
    	
0991425
    	
 
    	
30-Sep-05
    
	
 
    	
 
    	
AT
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/01157
    	
 
    	
 
    	
 
    	
0991425
    	
 
    	
30-Sep-05
    
	
 
    	
 
    	
DE
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/01157
    	
 
    	
 
    	
 
    	
0991425
    	
 
    	
30-Sep-05
    
	
 
    	
 
    	
FR
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/01157
    	
 
    	
 
    	
 
    	
0991425
    	
 
    	
30-Sep-05
    
	
 
    	
 
    	
NO
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/01157
    	
 
    	
 
    	
 
    	
0991425
    	
 
    	
30-Sep-05
    
	
 
    	
 
    	
GB
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/01157
    	
 
    	
 
    	
 
    	
0991425
    	
 
    	
30-Sep-05
    
	
 
    	
 
    	
CH
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/01157
    	
 
    	
 
    	
 
    	
0991425
    	
 
    	
30-Sep-05
    
	
 
    	
 
    	
GB
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/01157
    	
 
    	
 
    	
 
    	
0991425
    	
 
    	
30-Sep-05
    
	
 
    	
 
    	
JP
    	
 
    	
 
    	
 
    	
 
    	
 
    	
WO 99/01157
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
MX
    	
 
    	
 
    	
 
    	
 
    	
 
    	
WO 99/01157
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
US
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
 
    	
 
    	
 
    	
 
    	
6939862
    	
 
    	
6-Sep-05
    
	
 
    	
 
    	
PCT
    	
 
    	
 
    	
 
    	
 
    	
 
    	
WO 99/001158
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
EP
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/001158
    	
 
    	
 
    	
 
    	
0991426
    	
 
    	
 
    
	
 
    	
 
    	
GB
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/001158
    	
 
    	
 
    	
 
    	
0991426
    	
 
    	
 
    
	
 
    	
 
    	
BE
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/001158
    	
 
    	
 
    	
 
    	
0991426
    	
 
    	
 
    
	
 
    	
 
    	
FR
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/001158
    	
 
    	
 
    	
 
    	
0991426
    	
 
    	
 
    
	
 
    	
 
    	
DE
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/001158
    	
 
    	
 
    	
 
    	
0991426
    	
 
    	
 
    
	
 
    	
 
    	
IT
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/001158
    	
 
    	
 
    	
 
    	
0991426
    	
 
    	
 
    
	
 
    	
 
    	
CH
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/001158
    	
 
    	
 
    	
 
    	
0991426
    	
 
    	
 
    
	
 
    	
 
    	
NO
    	
 
    	
 
    	
 
    	
GRANTED
    	
 
    	
WO 99/001158
    	
 
    	
 
    	
 
    	
0991426Exhibit 10.3

 

EMPLOYMENT AGREEMENT

 

This Employment Agreement (the “Agreement”) is made this May 18, 2011, by and between OncoSec Medical Incorporated, a Nevada corporation (the “Company”) and Punit S. Dhillon (the “Employee” or “Executive”).  The Company or Employee are sometimes referred to herein as “party” or collectively the “parties”.

 

RECITALS

 

WHEREAS, the parties wish to provide for Employee to serve as President & Chief Executive Officer of the Company;

 

WHEREAS, the Company desires to employ the Executive and to have the benefit of his skills and services, and Executive desires to accept employment with the Company, on the terms and conditions set forth herein; and

 

WHEREAS, as a condition to his employment by the Company, Executive agrees to execute and shall be bound by the terms and conditions of the Proprietary Information, Invention, and Non-Compete Agreement (the “Non-Compete Agreement”) attached hereto as Exhibit A, and the Confidentiality Agreement, attached hereto as Exhibit B.

 

NOW, THEREFORE, in consideration of the mutual promises, terms, covenants and conditions set forth herein and in the Non-Compete Agreement, and the performance of each, the parties hereto, intending legally to be bound, hereby agree as follows:

 

Article 1.               Employment

 

1.1           Employment:  The Company hereby employs the Employee as of the Effective Date to serve as President & Chief Executive Officer (“CEO”), or in such other capacity as may be mutually agreed to by the parties, and the Employee accepts such employment, upon the terms and subject to the conditions set forth in this Agreement.

 

1.2           Duties:  The Employee shall perform such duties as are customarily associated with his then current title or titles, consistent with the Bylaws of the Company and as required by the Board of Directors (the “Board”) of the Company.  The Company and the Employee agree that the duties may be replaced, superseded or supplemented from time to time by the Board of Directors, but subject to the provisions of Section 4.3.1.3 of this Agreement.

 

1.3           Hours:  During the term of the Employee’s employment with Company, the Employee will devote his best efforts and substantially all of his business time and attention to the performance of his duties hereunder and to the business and affairs of the Company, except for vacation periods as set forth herein, or for such reasonable time periods to voluntarily perform charitable or civic duties by Employee.  The Employee will duly, punctually and faithfully observe the Company’s general employment policies and practices, including, without limitation, any and all rules, regulations, policies and/or procedures which the Company may now or hereafter establish governing the conduct of its business.  In addition, the Employee will carry out his duties honestly, in good faith and in the best interests of the Company.

 

1.4           Change of Control:  In the event of a Change of Control (as defined below), and except as provided in Section 4.3, the Company shall continue to engage the Employee, and the Employee shall continue to serve the Company, in the same capacity and have the same authority, responsibilities and status as he had as of the date immediately prior to the change of control, and under the same terms and 

 

1

 

conditions as set forth in this Agreement.  Upon a Change of Control, all outstanding options shall immediately vest.  For the purposes of this Agreement, a “Change of Control” shall be deemed to have occurred when any of the following have occurred:

 

1.4.1        a change in the composition of the Board over a period of twelve (12) months or less such that a majority of the Board members (rounded up to the next whole number) ceases, by reason of one or more contested elections for Board membership, to be comprised of individuals who are continuing directors;

 

1.4.2        a merger or consolidation in which the Company is not the surviving entity, except for a transaction the principal purpose of which is to change the state in which the Company is incorporated;

 

1.4.3        the sale, transfer or other disposition of all or substantially all of the assets of the Company;

 

1.4.4        the complete liquidation or dissolution of the Company;

 

1.4.5        any reverse merger or series of related transactions culminating in a reverse merger (including, but not limited to, a tender offer followed by a reverse merger) in which the Company is the surviving entity but (A) the shares of Common Stock outstanding immediately prior to such merger are converted or exchanged by virtue of the merger into other property, whether in the form of securities, cash or otherwise, or (B) in which securities possessing more than fifty percent (50%) of the total combined voting power of the Company’s outstanding securities are transferred to a person or persons different from those who held such securities immediately prior to such merger or the initial transaction culminating in such merger; or

 

1.4.6        acquisition in a single or series of related transactions by any person or related group of persons (other than the Company or by a Company-sponsored employee benefit plan) of beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Company’s outstanding securities..

 

1.5           Previous Agreements:  The parties hereby agree, that all previous employment, consulting or other similar agreements covering the same subject matter of this Agreement, whether written, verbal or implied between the Company and the Employee, are hereby cancelled, superseded and replaced by this Agreement, and shall be of no further force or effect.

 

Article 2.               Compensation

 

2.1           Salary:  Subject to subsection 2.2, for his services hereunder, the Employee shall receive a salary, payable in such regular intervals as shall be determined by the Company commencing on the Effective Date of this Agreement, which shall be at the rate of not less than U.S. $240,000 per year (the “Salary”).

 

2.2           Salary Increases:  The rate of Salary provided for in Section 2.1 shall be reviewed by the Board not less often than annually and shall be increased from time to time and in such amount as the Board, in its sole discretion, may determine.

 

2

 

2.3           Discretionary Bonus:  Beginning in 2011, the Company will, within 90 days of the end of the 2011 fiscal year and each subsequent fiscal year, determine the annual bonus (the “Bonus”), if any, payable to the Employee for that fiscal year, based on the Employee’s achievement of milestones agreed to by the Board or the Compensation Committee of the Board and the Employee.  Within 60 days of the beginning of each fiscal year, the Board or the Compensation Committee or the Board and the Employee shall agree to the Employee’s milestones and the amount of bonus, potentially payable if one or more milestones are achieved.  In the Company’s sole discretion it may pay the Bonus in cash, shares of the Company or stock options of the Company, or any combination thereof, and it may pay the Bonus in a lump sum or instalments, equal or otherwise, over the course of the six months immediately following the fiscal year for which the bonus was earned.  Notwithstanding anything herein to the contrary, the Employee must be employed on the date(s) the Bonus is to be paid to be eligible to receive the Bonus, or portion thereof.

 

2.4           Withholding:  All payments of Salary, Bonuses and other compensation pursuant to this Agreement shall be subject to withholding taxes and statutory deductions as required by law.  The Company shall be entitled to deduct from the Salary, Bonus and any other compensation due to the Employee, and to remit to the required governmental authority, any amount that it may be required by law or regulation to deduct, retain and remit, and may deduct other amounts as authorized by the Employee.

 

2.5           Stock Options:  In addition to the compensation provided for in section 2.1 of this Agreement, the Employee shall be entitled to such stock options as may be approved by the Board or the Compensation Committee of the Board in its sole discretion from time to time, subject to regulatory approval and subject to the terms and conditions set out in the OncoSec Medical Incorporated 2011 Stock Incentive Plan, or any other stock option plans subsequently adopted by the Company applicable to the Employee’s position, including all terms and conditions regarding vesting and exercise of options upon termination or other events.

 

Article 3.               Fringe Benefits

 

3.1           Participation in Plans:  The Employee shall be entitled to all additional fringe benefits, including, but not limited to, life and health insurance programs that may be generally available to other employees of the Company.  All matters of eligibility for coverage of benefits under any plan or plans of health, hospitalization, life or other benefits provided by the Company shall be determined in accordance with the provisions of the insurance policies and/or applicable benefit plans.  The Company shall not be liable to the Employee, or his beneficiaries or successors, for any amount payable or claimed to be payable under any plan or policy of insurance, which is not paid to any of the Company’s other employees.

 

3.2           Vacation:  The Employee shall be entitled to four (4) weeks of annual paid vacation. In addition, the Employee may be entitled to additional paid vacation during each calendar year, depending upon the length of the Employee’s employment with the Company, in accordance with the vacation accrual schedules and applicable vacation policies and procedures of the Company, including the maximum cap on accrual, as applied to other employees of the Company and which may be changed from time to time by the Company, but the paid vacation shall not be less than the amount of vacation Employee was entitled to receive from the Company as of the Effective Date.  Unused vacation days may be carried over to the subsequent year, however the Executive must take the vacation days within 10 months of the end of the year in which the vacation days were earned.

 

3.3           Business Expenses:  The parties acknowledge that the Employee may incur, from time to time, for the benefit of the Company and in furtherance of the Company’s business, various business expenses.  The Company agrees that it shall either pay such reasonable expenses directly, or reimburse the Employee 

 

3

 

for such reasonable expenses incurred by the Employee, within 15 business days of expense receipt.  The Employee agrees to promptly submit to the Company original receipts of all expenses paid by Employee and such other documentation as may be reasonably necessary to substantiate that all expenses paid or reimbursed hereunder were reasonably related to the performance of his or her duties, pursuant to the provisions of any applicable expense reimbursement policies and procedures that the Company may implement for time to time.

 

3.4           Tax Planning: The Company and the Executive agree to work with the relevant tax advisors to determine a mutually beneficial tax structure with respect to compensation payable to the Executive hereunder provided that such structure is not detrimental to the Company.

 

3.5           Personal Income Tax Return Preparation: The Company shall reimburse the Executive for personal income tax return advice and preparation for the 2011 and 2012 taxation years, up to a maximum of US$2,500 per year, provided that Executive is employed with the Company at the time the reimbursement is paid.

 

3.6           Legal Fees: The Company shall reimburse the Executive for legal expenses in connection to the review of this Agreement, upon submission of relevant receipts, to a maximum of $1,500.00.

 

3.7           Work Eligibility: The Company agrees to sponsor, prepare and file all necessary documents to provide the Executive with immigration and work permits for the United States while Executive is employed by the Company.

 

Article 4.               Term and Termination of Employment

 

4.1           Condition Precedent:  The obligations of the parties under this Agreement shall commence only upon the happening of the Effective Date as defined above, and the obligations of the Company under this Agreement are subject to the fulfillment of the condition that the Employee execute the Non-Compete Agreement attached hereto as Exhibit A and the Confidentiality Agreement attached hereto as Exhibit B.

 

4.2           Initial Term and Renewal:  The initial term of this Agreement shall be for a period of five (5) years commencing on the Effective Date (the “Initial Term”), unless terminated earlier pursuant to the provisions of Section 4.3 of this Agreement, unless either party gives written notice to the other party at least ninety (90) days prior to any Expiration Date that the Agreement is not being renewed and shall terminate on that Expiration Date.  The Initial Term and each successive one year period thereafter during which Employee shall perform services pursuant to this Agreement shall be referred to herein as the “Term.”

 

4.3           Termination:

 

4.3.1                        The Employee’s Right to Terminate:  The Employee may terminate his obligations under this Agreement during the Term:

 

4.3.1.1     at any time upon providing six weeks notice in writing to the Company; or

 

4.3.1.2     upon a material breach or default of any term of this Agreement by the Company, including any material reduction in salary, or

 

4.3.1.3     for “Good Reason” during the Initial Term or during any one year period immediately after a Change of Control.  “Good Reason” shall mean any of the following, without the Employee’s written consent: (a) Employee ceases to report directly to the Board of Directors of the Company provided that such change in reporting relationship results in a material reduction in Employee’s authority, duties, or responsibilities, or (b) any other material reduction in the Employee’s duties, authority or responsibilities with the Company relative to the duties, authority or responsibilities in effect immediately prior to such reduction.

 

4

 

Notwithstanding the foregoing, Employee may only terminate his or her employment pursuant to Section 4.3.1.2 or 4.3.1.3 if (x) he or she gives written notice to the Company within ninety (90) days of the initial existence of the event that gives rise to the material breach or default of this Agreement or Good Reason, (y) the event remains uncured for thirty (30) days after such notice is given by him or her, and (z) he or she terminates his or employment with the Company within ninety (90) days following the end of such thirty (30) day cure period.

 

4.3.2                        Company’s Right to Terminate for “Cause”:  The Company may immediately terminate the Employee’s employment for “Cause” under this Agreement at any time during the Term.  For the purposes of this Agreement, “Cause” shall include, without limitation, the following:

 

4.3.2.1     the Employee acting unlawfully, dishonestly, in bad faith or grossly negligent with respect to the business of the Company as determined by the Board; or

 

4.3.2.2     the Employee committing any crime or fraud against the Company or its property or the conviction of Employee of any felony offense or crime reasonably likely to bring discredit upon the Employee or the Company; or

 

4.3.2.3     a material breach or default of any term of this Agreement by the Employee if such material breach or default has not been remedied within 30 days after written notice of the material breach or default has been delivered by the Company to the Employee; or

 

4.3.2.4     any action by the Executive constituting misconduct, dishonesty, or neglect in the performance of his duties and responsibilities; or

 

4.3.2.5     any refusal to follow reasonable directions from the Board; or

 

4.3.2.6     conviction of the Executive for an indictable or summary offence; and

 

4.3.2.7     Any other matter that would constitute cause at law.

 

4.3.3                        Company’s Right to Terminate Without Cause: The Company may terminate the Employee’s employment under this Agreement at any time during the Term at the discretion of the Company, without Cause, after the Employee has received 30 days prior written notice from the Company.

 

4.3.4                        Other Termination:  The Employee’s employment under this Agreement shall also terminate upon the occurrence of the following:

 

4.3.4.1     the Employee’s employment under this Agreement shall automatically terminate upon the occurrence of the death of the Employee during the Term of this Agreement; or

 

5

 

4.3.4.2     notice of termination from the Company after the Employee has become permanently disabled, or disabled for a period exceeding 180 consecutive days or 180 days calculated on a cumulative basis over any one year period during the Term of this Agreement, such that Employee is no longer able to perform the essential functions of his job even with reasonable accommodation pursuant to applicable law.

 

4.3.5                        Compensation Due to the Employee on Termination:  In the event of the termination of the Employee’s employment under this Agreement pursuant to any provision as set forth above, the Company shall pay to the Employee on the date of termination only the amount of Salary pursuant to subsection 2.1 of this Agreement that is earned but unpaid as of the date of termination, as well as any accrued but unused vacation pay, and any unreimbursed business expenses incurred as of the termination date pursuant to subsection 3.3 of this Agreement, but Employee shall not be entitled to receive any other payments, compensation or benefits from the Company under this Agreement, except as expressly set forth below:

 

4.3.5.1     if terminated by the Employee pursuant to subsection 4.3.1.2 due to a material breach or default by the Company, or for Good Reason pursuant to subsection 4.3.1.3, or if terminated by the Company without Cause pursuant to subsection 4.3.3, the Company shall pay to the Employee the following additional amounts:

 

(a)                                  a severance payment in an amount equal to twenty-four (24) months of the Employee’s annual Salary at the time of Termination pursuant to subsection 2.1 of this Agreement, less applicable statutory deductions and withholdings, to be paid in accordance with the Company’s standard payroll practices in equal cash instalments beginning on the first payroll date following the date that the Severance Release (as defined in Section 4.3.6) becomes effective in accordance with its terms (the “Release Effective Date”) and ending on the second anniversary of the Employee’s termination date; and

 

(b)                                 an amount equal to the annual Bonus, if any, most recently paid to the Employee pursuant to subsection 2.3 of this Agreement, multiplied by the fraction of which the number of days between the fiscal year end of the Company related to the bonus and the date of termination is the numerator, and 365 is the denominator.

 

4.3.5.2     if terminated pursuant to subsection 4.3.4 due to death or disability, the Company shall pay to the Employee or his estate the following amount in addition to the Salary and vacation earned as of the date of termination and expense reimbursement as set forth above in subsection 4.3.5:

 

(a)                                  an amount equal to the annual Bonus, if any, most recently paid to the Employee pursuant to subsection 2.3 of this Agreement, multiplied by the fraction of which the number of days between the fiscal year end of the Company related to the bonus and the date of termination is the numerator, and 365 is the denominator.

 

6

 

4.3.5.3     If Employee’s employment is terminated pursuant to subsections 4.3.1.2, 4.3.1.3 or 4.3.3, and any spouse and/or dependents of the Employee (“Family Members”), has coverage on the date of the Employee’s termination under a group health plan sponsored by the Company, the Company will pay for a period of up to twenty-four (24) months the total applicable premium cost for continued group health plan coverage under the Consolidated Omnibus Budget Reconciliation Act of 1986, 29 U.S.C. Sections 1161-1168; 26 U.S.C. Section 4980B(f), as amended, and all applicable regulations (referred to collectively as “COBRA”), provided that the Employee is eligible for and validly elects to continue coverage under COBRA for the Employee and his Family Members.  No other benefits shall be continued.

 

4.3.6                        Release. The receipt of any payment pursuant to Section 4.3.5 above will be subject to Employee timely signing and not revoking a standard release of all claims as presented by the Company (the “Severance Release”). To be timely, the Severance Release must become effective and irrevocable no later than sixty (60) days following the date of the Employee’s termination (the “Severance Release Deadline”). If the Severance Release does not become effective and irrevocable by the Severance Release Deadline, Employee will forfeit any rights to the severance benefits described in Section 4.3.5. In no event will any severance benefits be paid under Section 4.3.5, above, until the Severance Release becomes effective and irrevocable.

 

Article 5.               Miscellaneous

 

5.1           Assignment Prohibited:  This Agreement is personal to the Employee hereto and Employee may not assign or delegate any of Employee’s rights or obligations hereunder.  The Company may not assign this Agreement without the written consent of the Employee except in connection with a merger or consolidation of the Company (in which case the merged or consolidated entity shall remain fully liable for its obligations as the Company under this Agreement as specified above).

 

5.2           Paragraph Headings:  The paragraph headings used in this Agreement are included solely for convenience and shall not affect of be used in connection with the interpretation of this Agreement.

 

5.3           Legal Expenses of Enforcement:  If either party commences a legal action or other proceeding for enforcement of this Agreement, or because of an alleged dispute, breach, default or misrepresentation in connection with any of the provisions of this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees and other costs incurred in connection with the action or proceeding, in addition to any other relief to which it may be entitled.

 

5.4           Independent Legal Advice:   Employee acknowledges and understands that this Agreement was drafted and prepared for the Company with the assistance of legal counsel and that such legal counsel has not been engaged to protect the rights and interests of Employee to this Agreement.  Employee further acknowledges and agrees that the Company has given Employee an adequate opportunity to seek, and Company has recommended that Employee seek and obtain, independent legal advice with respect to the subject matter of this Agreement and for the purpose of ensuring that Employee’s rights and interests are protected.  Employee represents and warrants to the Company that Employee has sought independent legal advice, or has consciously chosen not to do so with full knowledge of the risks associated with not obtaining such independent legal advice.

 

5.5           Severability:  If any provision of this Agreement is declared invalid by any court or tribunal, then such provision shall be deemed automatically modified to conform to the requirements for validity as declared at such time, and as so modified, shall be deemed a provision of this Agreement as though originally included herein.  In the event that the provision invalidated is of such a nature that it cannot be so modified, the provision shall be deemed deleted from this Agreement as though the provision had never been included herein.  In either case, the remaining provisions of this Agreement shall remain in effect.

 

7

 

5.6           Choice of Law:  This Agreement shall be governed by and construed in accordance with the laws of the State of California, as applied to agreements executed and performed entirely in California by California residents without regard to California’s choice of law rule.

 

5.7           Entire Agreement:  This Agreement constitutes the entire, final and complete and exclusive agreement between the parties regarding the subject matter hereof and supersedes all previous agreements or representations, whether written, oral or implied, with respect to employment by the Company provided, however, the Employee shall remain bound by any confidentiality, invention assignment, non-solicit and non-compete agreement(s) previously executed in favor of the Company, to the extent such ancillary agreements exist.  There are no terms, promises, representations, agreements, or understandings between the parties relating to the subject matter of this Agreement, which are not fully expressed herein.

 

5.8           Change, Modification, Waiver:  No change or modification of this Agreement shall be valid unless it is in writing and signed by each of the parties hereto.  No waiver of any provision of this Agreement shall be valid unless it is in writing and signed by the party against whom the waiver is sought to be enforced.  The failure of a party of insist upon strict performance of any provision of this Agreement in any one or more instances shall not be construed as a waiver or relinquishment of the right to insist upon strict compliance with such provision in the future.

 

5.9           Notices:  All notices required or permitted hereunder shall be in writing and shall be delivered to the other party in person or sent by overnight currier with confirmation of delivery, or by regular mail, postage prepaid, at the address first written above or at such other address as provided in writing or currently on record at the Company at the time notice is sent.

 

5.10         Binding Effect:  This Agreement shall be binding upon, and inure to the benefit of, the parties, their heirs, successors and assigns.

 

8

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

ONCOSEC MEDICAL INCORPORATED

 

	
Per:
    	
 
    
	
 
    	
 
    
	
/s/ Avtar Dhillon
    	
 
    
	
Authorized Signatory
    	
 
    
	
Date:
    	
May   18, 2011
    	
 
    
	
 
    	
 
    
	
Authorized Signatory
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/ Punit Dhillon
    	
 
    
	
Punit Dhillon
    	
 
    
	
Date:
    	
May   18, 2011
    	
 
    

 

9

 

ANNEX A

 

SECTION 409A ADDENDUM

 

Notwithstanding anything to the contrary in the Agreement, no severance pay or benefits to be paid or provided to the Executive, if any pursuant to the Agreement that, when considered together with any other severance payments or separation benefits, are considered deferred compensation under Section 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and any guidance promulgated thereunder (“Section 409A”) (together, the “Deferred Payments”) will be paid or otherwise provided until the Executive has had a “separation from service” within the meaning of Section 409A.  Similarly, no severance payable to the Executive, if any, that otherwise would be exempt from Section 409A pursuant to Treasury Regulation Section 1.409A-1(b)(9) will be payable until the Executive has had a “separation from service” within the meaning of Section 409A.  Each payment and benefit payable under the Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations.

 

Any severance payments or benefits under the Agreement that would be considered Deferred Payments will be paid or will commence on the sixtieth (60th) day following the Executive’s separation from service, or, if later, such time as required by the next paragraph.

 

Notwithstanding anything to the contrary in the Agreement, if the Executive is a “specified employee” within the meaning of Section 409A at the time of the Executive’s termination (other than due to death), then the Deferred Payments that would otherwise have been payable within the first six (6) months following the Executive’s separation from service, will be paid on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of the Executive’s separation from service, but in no event later than seven months after the date of such separation from service.  All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.  Notwithstanding anything herein to the contrary, if the Executive dies following the Executive’s separation from service, but prior to the six (6) month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of the Executive’s death and all other Deferred Payments will be payable in accordance with the payment schedule applicable to each payment or benefit.

 

Any amount paid under the Agreement that satisfies the requirements of the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments.  Any amount paid under the Agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constituted Deferred Payments.  For this purpose, the “Section 409A Limit” will mean two (2) times the lesser of: (i) the Executive’s annualized compensation based upon the annual rate of pay paid to him during the Executive’s taxable year preceding his taxable year of his separation from service as determined under Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Internal Revenue Code for the year in which the Executive’s separation from service occurred.

 

The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply.  The Company and the Executive agree to work together in good faith to consider amendments to the Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to the Executive under Section 409A.

 

1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}]]